Stock data
Nektar Therapeutics (NKTR)
Nektar Therapeutics (NKTR) reported revenue of US$55.23M and net income of -US$164.08M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$55.23M | — | -US$140.10M | -US$164.08M | — |
| 2024 | US$98.43M | — | -US$105.20M | -US$118.96M | — |
| 2023 | US$90.12M | — | -US$263.68M | -US$276.06M | — |
| 2022 | US$92.06M | — | -US$376.17M | -US$368.20M | — |
| 2021 | US$101.91M | — | -US$446.10M | -US$523.84M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$10.13M | -US$40.62M | — |
| 2026-03-31 | US$10.86M | -US$44.90M | — |
| 2025-12-31 | US$21.81M | -US$36.08M | — |
| 2025-09-30 | US$11.79M | -US$35.52M | — |
| 2025-06-30 | US$11.18M | -US$41.59M | — |
| 2025-03-31 | US$10.46M | -US$50.88M | — |
| 2024-12-31 | US$29.18M | US$7.26M | — |
| 2024-09-30 | US$24.12M | -US$37.06M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.